The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

USA

https://clinicaltrials.gov/study/NCT07095127?cond=ITP%20-%20Immune%20Thrombocytopenia&aggFilters=status:rec&term=NCT07095127&rank=1

Actively Recruiting